Financial reports
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
11 Apr 23
NT 10-K
Notice of late annual filing
3 Apr 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
30 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
10-Q
2021 Q2
Quarterly report
6 Aug 21
10-Q
2021 Q1
Quarterly report
14 May 21
Current reports
8-K
Submission of Matters to a Vote of Security Holders
7 Aug 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
8-K
Entry into a Material Definitive Agreement
20 Jun 23
8-K
2021 Annual Stockholders Meeting
15 Nov 21
8-K
Regulation FD Disclosure
22 Jul 21
8-K
Entry into a Material Definitive Agreement
1 Jul 21
8-K
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
14 May 21
8-K
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
19 Mar 21
8-K
Entry into a Material Definitive Agreement
21 Oct 20
8-K
RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome
13 Oct 20
Registration and prospectus
15-12G
Securities registration termination
14 Aug 23
424B3
Prospectus supplement
17 Nov 21
S-1/A
IPO registration (amended)
2 Sep 21
S-1
IPO registration
17 Aug 21
424B3
Prospectus supplement
18 Aug 20
424B3
Prospectus supplement
18 Aug 20
424B3
Prospectus supplement
30 Mar 20
424B3
Prospectus supplement
30 Mar 20
424B3
Prospectus supplement
19 Nov 19
424B3
Prospectus supplement
19 Nov 19
Proxies
DEF 14A
Definitive proxy
11 Jul 23
PRE 14A
Preliminary proxy
23 Jun 23
DEFR14A
Revised proxy
19 Oct 21
DEF 14A
Definitive proxy
18 Oct 21
PRE 14A
Preliminary proxy
8 Oct 21
DEFA14A
Additional proxy soliciting materials
10 Sep 19
DEF 14A
Definitive proxy
30 Aug 19
PRE 14A
Preliminary proxy
21 Aug 19
DEF 14A
Definitive proxy
15 May 18
DEF 14A
Definitive proxy
16 Sep 16
Other
EFFECT
Notice of effectiveness
7 Sep 21
CORRESP
Correspondence with SEC
3 Sep 21
UPLOAD
Letter from SEC
19 Aug 21
EFFECT
Notice of effectiveness
24 Oct 18
CORRESP
Correspondence with SEC
22 Oct 18
UPLOAD
Letter from SEC
18 Oct 18
CT ORDER
Confidential treatment order
12 Dec 17
EFFECT
Notice of effectiveness
3 Aug 16
CORRESP
Correspondence with SEC
2 Aug 16
UPLOAD
Letter from SEC
25 Jul 16